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Biomarkers also help to avoid invasive procedures which are often a
burden to the patient and the health care system. If an ideal biomarker
existed for UC, it would greatly facilitate the work of the gastroenterolo-
gisttreatingthesepatients.Both“classical”and“emerging”biomarkers
of relevance for UC have been studied, but the quest for an ideal bio-
marker still continues. In this brief review we describe various biomark-
ers of clinical importance.
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Zusammenfassung
In den letzten beiden Dekaden sind mehrere Versuche unternommen
worden, geeignete Marker für die Diagnose und den Verlauf der Colitis
ulcerosa zu finden. In den Ruhephasen der Erkrankung haben die
meisten Patienten schwach ausgeprägte Zeichen der Entzündung. Es
istmöglich,dassderRückfallnurauftritt,wennderEntzündungsprozess
eine kritische Intensität überschreitet. Da die Entzündung ein kontinu-
ierlicher Prozess ist, könnte ihre direkte Erfassung eine quantitative
Messgröße für den drohenden Rückfall bilden. Wenn wesentliche Ver-
änderungen auftreten, könnte eine frühe gezielte Therapie eingeleitet
werden, um den Rückfall zu vermeiden oder neuere therapeutische
Strategien entwickelt werden, um eine symptomatische Remission zu
erzielen. Es ist klinisch von großer Bedeutung, auf nicht-invasivem
WegemitHilfevonBiomarkerndiesePatientenbereitsimsubklinischen
Stadium der Erkrankung zu erfassen. Biomarker ermöglichen, die Er-
krankungsaktivität objektiv zu erfassen, weil die Symptome häufig
subjektivsind.Biomarkerhelfenauch,invasive Prozeduren,diefürden
Patienten sehrbelastendundkostenträchtigsind,zu vermeiden.Wenn
ein idealer Biomarker für die ulcerative Colitis existieren würde, könnte
dieser bei der gastroenterologischen Behandlung vieler Patienten hilf-
reich sein. Sowohl klassische als auch neu gefundene Biomarker von
Bedeutung wurden untersucht, aber die Suche nach einem idealen
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verschiedene Biomarker von klinischer Bedeutung beschrieben.
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Introduction
Ulcerative colitis has remissions and relapses, so both
the patient and the treating physician need to have a
coordinated approach. Treatment modalities may range
from drugs with lot of side effects to surgical interven-
tions. The disease is usually chronic and the aim of
treatment in active disease is to induce remission. The
gastrointestinaladvisorypaneloftheAmericanFoodand
Drug Administration has proposed that remission be
definedasanabsenceofinflammatorysymptoms(rectal
bleeding or diarrhea) in conjunction with evidence of
mucosal healing (absence of ulceration, significant
granularityorfriability).Whilerepeatedendoscopicexam-
ination is not always thought desirable by patient or
clinician,asimplemarkeroracombinationofbiomarkers
of intestinal inflammation would be of great help in
monitoringtheresponsetotreatment.Theshortcomings
of clinicalindicesin assessingdiseaseactivity are widely
known. Also in subjects with previously diagnosed UC it
is sometimes not clear whether symptoms are due to
active inflammatory bowel disease or an overlying func-
tional bowel disorder, which commonly co-exists in pa-
tients with inflammatory bowel disease [1]. There is no
single “Gold Standard” test or examination for diagnosis
of UC, instead physicians apply a combination of symp-
toms,clinicalexamination,laboratoryindices,endoscopy
and histology to make the diagnosis and to assess
severity as well as predict the outcome of disease [2].
Biomarkers have been studied in the past decade firstly
to gain an objective measurement of disease activity as
symptoms are often subjective and secondly to avoid in-
vasive(endoscopic)procedureswhichareoftenaburden
to the patient and to health care system as well.
Markers in serum
Serum C-reactive protein
Alargenumberofchanges,distantfromthesiteofinflam-
mation and involving many organ systems, may accom-
pany inflammation. In 1930, interest was focused on
these changes by the discovery of C-reactive protein [3]
(CRP;socalledbecauseitreactedwiththeplasmaofthe
patients during the acute phase of pneumococcal pneu-
monia).Denovohepaticsynthesisstartsveryrapidlyafter
a single stimulus, serum concentration rising above
5mg/Lbyabout6hrsandpeakingaround48hours.The
plasma half life of CRP is about 19 hours and is constant
under all conditions of health and disease, so that the
soledeterminantsofcirculatingCRPconcentrationisthe
synthesis rate which thus directly reflects the intensity of
the pathological process stimulating CRP production.
When the stimulus for increased production completely
ceases, the circulating CRP concentration falls rapidly,
at almost the rate of plasma CRP clearance [4]. Twin
studies show a highly significant hereditable component
in base line CRP values that are independent of age and
body mass index (BMI). In most, though not all diseases,
thecirculatingvalueofCRPreflectongoinginflammation
and tissue damage much more accurately than do other
laboratoryparametersoftheacutephaseresponse,such
as plasma viscosity and the erythrocyte sedimentation
rate(ESR).Importantly,acutephaseCRPvaluesshowno
diurnal variation and are unaffected by eating. Further-
more, no anti-inflammatory or immunosuppressive drug
affects CRP production. Therefore, modification of CRP
response during treatment occurs only as a result of the
effect of drug on underlying disorder. Serum CRP as a
biomarker in the course of UC has been studied by num-
ber of workers. Prantera et al. [5] studied 60 UC patients
andconcludedthatthediseaseseverityandthepresence
of signs and symptoms of toxicity seem likely to be de-
termined by the amount of colonic tissue involved by in-
flammation, both in depth and in extent. CRP appeared
the most reliable factor reflecting activity and extension
of lesion. In a study from Mayo Clinic [6], a cohort of
43UCpatientswerestudied.Theauthorsconcludedthat
serum CRP levels were associated with increase in bio-
markers of inflammation (except platelets) and an active
diseaseat ileocolonoscopy. However, histologicalactivity
was not associated with CRP concentrations in UC pa-
tients.InanotherstudyChouhanetal.[7]concludedthat
measurementofCRPlevelsisasimplemethodofassess-
ingdiseaseactivityandextentinUC.CRPlevel>12mg/L
is indicative of severe and extensive disease. A change
in CRP following therapy is a good parameter to assess
the effect of the drug on the underlying inflammation. A
decrease in CRP in response to therapy is objective
evidence that the drug has a beneficial effect on gut in-
flammation even in patients with little change in symp-
toms.Ontheotherhand,persistentlyraisedCRPindicates
failure of the therapy to control mucosal inflammation
[8]. A very important clinical scenario in the course of UC
isseverecolitis:whenaclinicianisfacedwithachallenge
of sparing the colon and saving the life. Studies have
shown that on day 3 of intensive management with ster-
oids and serum CRP >45 mg/L , stool frequency greater
than 8, a surgical intervention may become life saving.
However, patterns of colitis, radiographic appearance,
age of the patient and last but not the least experience
of the treating physician can never be underestimated in
this decision.
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The presence of active gut inflammation in patients with
UCisassociatedwithanacutephasereactionandmigra-
tion of leucocytes to the gut, and this is transferred into
theproductionofseveralproteins,whichmaybedetected
in serum or stools [9]. Evaluation of whether mucosal in-
flammation is present or not is very important in the
management of patient with UC because relapse rates
are very high if minimal mucosal inflammation remains
in a patient who has clinical remission [10], [11]. Even
colonoscopydoesnotdetectinflammationifitisminimal
or localized. It is conceivable that feces reflect the state
of all sites in the digestive tract, since feces are formed
during transit of the bowel [12]. Fecal markers fulfill all
the criteria of being non-invasive, simple, in-expensive,
sensitive and specific parameters to detect gastrointes-
tinalinflammation.Fecalneutrophilderivedproteinshave
been the subjects of a number of reports; Sugi et al. [13]
concluded in their study that lactoferrin is the most suit-
able of these proteins to be used as a neutrophil-derived
fecal marker of inflammation for clinical applications.
Chronicinflammationofthelargeintestinepredominantly
comprisesoflymphocytesandplasmacellswhileinacute
exacerbation neutrophils migrate and degranulate sub-
stances like myeloperoxidase (MPO), lactoferrin, eosino-
philic chemotactic factors etc. The levels of these sub-
stances indicate activation of neutrophils along gut mu-
cosa during exacerbation. These substances are stable
in fecal matter and measurement of these can give indir-
ect evidence of colonic inflammation in a non-invasive
manner [13]. Fecal markers comprise a heterogeneous
group of substances that either leak from, or are gener-
ated by the inflamed intestinal mucosa. The main use of
these markers is likely to be in diagnosing and assessing
disease activity in difficult cases. They may also have a
role in assessing treatment effect and prediction of re-
lapse. Many potential markers have been assessed to
date; however, an ideal one is yet to be identified [14].
Fecal myeloperoxidase (MPO)
Neutrophil accumulation in the inflamed intestinal mu-
cosa is a prominent feature in ulcerative colitis. The
granules of neutrophil granulocytes contain a number of
enzymes,forexamplemyeloperoxidasewhichareimport-
ant in the combat against bacteria. These granule en-
zymes, some of which are proteolytic can be released
uponstimulation,togetherwithcytotoxicoxygenmetabol-
ites. Therefore activated neutrophils may contribute to
tissue damage at sites of inflammation. The factors re-
sponsible for the mucosal recruitment of neutrophils in
ulcerative colitis are not certain [15]. Myeloperoxidase
activity is directly related to cell number, down to as few
as 500 cells. Myeloperoxidase activity was assayed in
two animal models of inflammation: acetic acid induced
colitisinratsand Clostridiumdifficile enterotoxininduced
enteritis in hamsters. In both models, the activity of
myeloperoxidasesolubilizedfromtheinflamedtissuewas
directly proportional to the number of neutrophils seen
in histologic sections [16], [17]. Raab et al. [18] studied
the concentration of myeloperoxidase, a neutrophil
granule constituent, in the perfusion fluid from sigmoid
and rectal segments in patients with ulcerative colitis.
The concentrations of myeloperoxidase were increased
several fold in the patients with ulcerative colitis com-
pared with healthy controls pointing to an enhanced
neutrophilactivity.Thereleaseofmyeloperoxidasecorrel-
ated to an enhanced local release of the neutrophil acti-
vating peptide interleukin-8 (IL8). The results obtained
are compatible with the hypothesis that local mucosal
recruitment/activation of neutrophil in ulcerative colitis
ismediatedbyanenhancedIL8synthesis.TNF-αmaybe
onerelevantfactorasastimulustoIL8synthesis.Bustos
etal.[19]solubilizedfecalMPOwithhexadecyltrimethyl-
ammoniumbromideandtheMPOactivitywasmeasured
by a diamisidine H2O2 assay. In their study, fecal leuko-
cytes were not found in healthy controls and stool MPO
activityrangedfrom1.6x10
3to2.83x10
3MPOpergram
of feces; the authors concluded that fecal MPO activity
is a simple biochemical assay for the detection and
quantification of fecal leukocytes. Later Saiki et al. [20]
studiedMPOlevelsinstoolextractswhichweremeasured
usingaradio-immunoassayin33patientswithulcerative
colitis and 15 normal controls. Stool levels of MPO in
active UC patients increased significantly and correlated
with laboratory parameters and endoscopic grade of in-
flammation.ApairedanalysisshowedadecreaseinMPO
levelsaftertheresolutionofdiseaseexacerbation.These
results suggest that stool MPO is a simple, non-invasive
and relevant marker of diseaseactivity. FecalMPO levels
can detect intestinal healing after treatment in a non in-
vasive manner. This can be reassuring to the treating
physician and high levels can predict relapse in a given
patient.InastudybySangfeltetal.[21]therectalrelease
oftheneutrophilMPOandeosinophilconstituents(eosin-
ophilic cationic protein ECP, eosinophil peroxidase EPO
granule)weremeasuredin11patientsusingintraluminal
segmentalperfusionoftherectum.Thereleasedamounts
of MPO, ECP and EPO in the perfusion fluids were deter-
mined by radio-immunoassays before and during pred-
nisolone enema treatment and correlated to clinical, en-
doscopic and histopathological data in addition to treat-
ment outcome. In their study rectally released MPO
seemed to be an early marker of treatment response in
patients with ulcerative colitis. Further more, when the
different granule products monitored in this study were
compared, MPO was best associated with inflammatory
activity and disease response to treatment.
Fecal lactoferrin
Lactoferrin, an iron binding protein with a molecular
weight of approximately 80,000, is present in the intes-
tinal mucus besides other body fluids. It has an antibac-
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terialeffect.Uchideetal.developedELISA(enzyme-linked
immunosorbent assay) and have shown that fecal lacto-
ferrinlevelishighinpatientswithcolorectaldisease[22].
Later Langhorst et al. [23] studied 76 fecal specimens
from 31 patients with UC in times of active and inactive
status of disease. Disease activity was determined with
the colitis activity index, which includes a combination of
laboratoryparametersandclinicalsymptoms,withascore
ofatleast6indicatingactivedisease.Lactoferrinshowed
increased levels in samples from patients with active
disease compared with those in remission. In another
study Kane et al. [24] studied fresh stool samples of
80 UC patients and 31 irritable bowel syndrome (IBS)
patients. Fecal lactoferrin concentrations were deter-
minedusingapolyclonalantibodybasedonELISA.Mean
fecal lactoferrin concentrations for each group and
sensitivityandspecificityweredeterminedbytheauthors.
The authors concluded that fecal lactoferrin was 90%
specificforidentifyinginflammationinpatientswithactive
UC and 100% specific in ruling out IBS.
Fecal calprotectin
Calprotectin is a calcium-binding protein that inhibits
metalloproteinases. It has antibacterial and antifungal
activities [25]. It is an abundant protein found in all body
fluids. Calprotectin has many clinical advantages to be
used as a non-invasive marker. It is resistant to bacterial
degradation in the gut and is stable in stool for up to one
week at room temperature, overcoming delays in trans-
portingthesampletothelaboratory.Furthermore,calpro-
tectincanbereadilyquantifiedusingELISA.Sincecalpro-
tectinisprimarilyderivedfromneutrophils,itsconcentra-
tionisdirectlyproportionaltoneutrophilmigrationtoward
the intestinal tract. From this comparison, levels of all of
the fecal leukocyte markers in IBS were found to be in
therangeofhealthycontrols.Fecalcalprotectinwasfound
to be strongly associated with colorectal inflammation,
indicating the presence of organic disease [26] and can
differentiate inflammatory bowel disease (IBD) from irrit-
able bowel syndrome. Studies have shown that fecal
calprotectin differentiated an inactive disease from mild,
moderate and highly active diseases, highlighting its
usefulnessformonitoringactivity[27].Inafollow-upstudy
of 163 patients (89 Crohn's disease (CD), 74 UC) over a
periodof12monthsGisbertetal.[28]evaluatedtherole
of fecal calprotectin and lactoferrin in the prediction of
IBD relapse. In patients who relapsed during follow-up
calprotectinconcentrationswerefoundtobehigherthan
in patients who had not (239 ±150 versus 136 ±158
µg/g (P<0.001). The relapse risk was higher in patients
that had high (>150 µg/g) calprotectin concentrations
(30% versus 7.8%; P<0.001) or positive lactoferrin (25%
versus 10%; P<0.05). The sensitivity and specificity of
fecal calprotectin (>150 µg/g) to predict relapse were
69% and 69%, respectively. The corresponding values
for lactoferrin were 62% and 65%, respectively. The au-
thors concluded that these markers are effective in pre-
dictingtherelapse.Fecalcalprotectinisaneasy,inexpen-
sive, sensitive and specific way to evaluate IBD. Despite
thefactthatlevelsoffecalcalprotectinhaveanimportant
role in diagnosis, follow-up, prediction of relapses and
assessment of response to treatment, it still has some
disadvantagesandcanonlybeusedasacomplementary
test.Fecalcalprotectinlevelsgetaffectedbynonsteroidal
anti-inflammatory drug (NSAID) intake, bleeding more
than 100 ml and by malignancy. Renata et al. [29] com-
paredfecallactoferrinwithcalprotectinin46UCpatients
(26 had extensive colitis and 20 had left sided colitis);
36(78%)patientshadactivediseaseatcolonoscopyand
calprotectin was above normal in 28 patients, as was
lactoferrinin27.Intheirstudy,endoscopicandhistologic
scorescorrelatedsignificantlywithlactoferrin.Theauthors
concluded that both calprotectin and lactoferrin tests
appear to be useful in detecting bowel inflammation in
symptomatic patients, achieving a similar diagnostic ac-
curacy as shown in Table 1. The proportion of patients
positive for calprotectin or lactoferrin was not influenced
by the extent of disease when a similar disease activity
was considered.
Comparison of serum and fecal
biomarkers in assesing disease
severity in UC
Westudiedbothserumandfecalbiomarkersinassessing
disease severity of UC and response to treatment. In this
prospective study [30] cases had significantly higher
levels of serum CRP, fecal lactoferrin and MPO levels
than controls, making biomarkers an excellent tool in
differentiationoffunctionalbowelsyndromesfrominflam-
matory bowel disorders. We observed that cases with
severe UC had higher CRP, MPO and fecal lactoferrin
levels than those with mild disease. All three markers
showed a high degree of correlation with each other.
There was significant correlation between severity of UC
and serum CRP levels and it was 100% specific. Fecal
lactoferrin was 94% sensitive and 100% specific and
fecal MPO was 89% sensitive and 51% specific. The
clinical improvement correlated with significant fall in all
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threebiomarkersonfollowupdepictingintestinalhealing.
We found these biomarkers to be excellent in assessing
disease severity and response to treatment in a non-in-
vasive manner.There are no guidelines for clinical use of
biomarkers yet. The algorithm in Figure 1 may be useful
for clinical practice.
Future biomarkers
In a recent study [31] of gene expression profiles from
blood of patients with ulcerative colitis, Crohn's disease
andnon-inflammatorydiarrhealdisorders,Burakoffetal.
demonstrated that different genes existed for each of
these disorders. Gene profiles could differentiate these
disorders in a given patient in a non-invasive manner.
Howevermorestudiesarerequiredbeforethesebiomark-
ers will come into clinical practice. The cost factor may,
however, become a limiting factor in their wider use.
Colorectal carcinoma is the most severe complication in
ulcerativecolitis.InanexperimentalanimalmodelTalero
etal.[32]observedthatdysplasiaandadenocarcinomas
correlated with number of cycles of dextran sulfate sodi-
um (DSS) induced colonic inflammation. The authors
observedthatadrenomedullinisimplicatedincarcinogen-
esis.Thismoleculeorsimilarothermoleculemaybecome
one of the future biomarkers in the management of ul-
cera-tive colitis so that patients with ulcerative colitis are
treated before dysplasia progresses to malignancy.
Conclusion
In conclusion, biomarkers are useful in differentiating
functional bowel disorders from inflammatory bowel dis-
ease. These are useful in assessing disease activity and
severity of ulcerative colitis. Using biomarkers, intestinal
healing after treatment can be documented on follow-up
in a non-invasive manner. This would be of great help in
monitoring response to treatment. Biomarkers can play
a role in determining relapse and can help in tailoring
treatmentwithoutrepeatingcolonoscopy.Diseaseassess-
ment by biomarkers may lead to new management ap-
proaches in UC if a perfect one or a combination of bio-
markers are discovered, as the quest for a perfect bio-
marker in ulcerative colitis still continues.
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